As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of NovaBridge Biosciences. The largest reported stake is Everest Medicines Limited's, at 16.1%. 4 filings are on record since August 5, 2025 (Schedule 13D, August 5, 2025).
Sell to companies like NovaBridge Biosciences? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: HHLR Advisors, Ltd. · Percent: 4.9% · Shares: 13,295,306 · SCHEDULE 13D/A
- · Holder: CBC Investment I-Mab Limited · Percent: 11.5% · SCHEDULE 13D/A
- · Holder: CBC Investment I-Mab Limited · Percent: 10.4% · SCHEDULE 13D/A
- · Holder: Everest Medicines Limited · Percent: 16.1% · Shares: 42,524,716 · SCHEDULE 13D
NovaBridge Biosciences has 4 Schedule 13D or 13G filings on record since 2025-08-05. 2 holders' latest filing reports 5% or more of ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Everest Medicines Limited | 16.1% | 42,524,716 | SCHEDULE 13D, 2025-08-05 | 2025-08-05 |
| CBC Investment I-Mab Limited | 11.5% | 11,784,164 | SCHEDULE 13D/A, 2026-02-03 | 2026-01-29 |
| HHLR Advisors, Ltd. | 4.9% | 13,295,306 | SCHEDULE 13D/A, 2026-11-05 | 2026-11-05 |
Holding shares or following this stake? See who's behind NovaBridge Biosciences and the warning signs.
Free to see. No signup.
Keep reading
More on NovaBridge Biosciences and the records around it.
NovaBridge Biosciences elsewhere on the record
Watch NovaBridge Biosciences
Get an email when NovaBridge Biosciences files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NovaBridge Biosciences?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on NovaBridge Biosciences: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NovaBridge Biosciences covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| HHLR Advisors, Ltd. | 0 | 13,295,306 | 0 | 13,295,306 | SCHEDULE 13D/A, 2026-11-05 |
| Hillhouse Investment Management, Ltd. | 0 | 13,295,306 | 0 | 13,295,306 | SCHEDULE 13D/A, 2026-11-05 |
The latest filing identifies NovaBridge Biosciences by CUSIP 44975P103 and gives its principal executive office as SUITE 400, 2440 RESEARCH BLVD, ROCKVILLE, MD 20850 (SCHEDULE 13D/A, 2026-11-05).
Purpose of Transaction (Item 4)
Everest Medicines Limited
The information set forth in or incorporated by reference in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person purchased the aforementioned securities for investment purposes with the aim of increasing the value of its investments and the Issuer. Subject to applicable legal requirements, the Reporting Person may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Person's ownership of the Issuer's securities, other opportunities available to the Reporting Person, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Person may dispose of all or a portion of their securities of the Issuer at any time. The Reporting Person reserves the right to increase or decrease its holdings on such terms and at such times as each may decide. Except as set forth in this Item 4 and Item 6 below, the Reporting Person does not have a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Securities Exchange Act of 1934 (the "Act"). However, the Reporting Person reserves the right to propose or …The first part of Item 4 of the SCHEDULE 13D filed 2025-08-05; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Everest Medicines Limited | 16.1% | SCHEDULE 13D |
| 2025-08-07 | CBC Investment I-Mab Limited | 10.4% | SCHEDULE 13D/A |
| 2026-02-03 | CBC Investment I-Mab Limited | 11.5% | SCHEDULE 13D/A |
| 2026-11-05 | HHLR Advisors, Ltd. | 4.9% | SCHEDULE 13D/A |
Questions about who owns NovaBridge Biosciences
Who owns NovaBridge Biosciences?
On this page, 2 holders' latest ownership filings report 5% or more of NovaBridge Biosciences: Everest Medicines Limited (16.1%, Schedule 13D, filed 2025-08-05) and CBC Investment I-Mab Limited (11.5%, Schedule 13D/A, filed 2026-02-03).
Who are the largest shareholders of NovaBridge Biosciences?
By the share each holder's latest filing reports, the largest holders of NovaBridge Biosciences on this page are Everest Medicines Limited (16.1%) and CBC Investment I-Mab Limited (11.5%).
When did Everest Medicines Limited buy into NovaBridge Biosciences?
The filings give report dates, not purchase dates. The earliest filing from Everest Medicines Limited on this page is the Schedule 13D, filed 2025-08-05, reporting 16.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for NovaBridge Biosciences. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.